 Patients with rectal adenocarcinoma of intermediate risk defined by magnetic resonance imaging MRI, without mutations in KRAS, BRAF, NRAS and PI3KCA, who are candidates for preoperative treatment, will receive a preoperative Induction therapy with 12 weeks of panitumumab with mFOLFOX-6 to evaluate the efficacy in terms of pathologic complete response pCR 